[Invasive pulmonary aspergillosis complicating septic shock].
BACKGROUND
Invasive pulmonary aspergillosis (IPA) is an opportunistic infection with a poor prognosis, occurring primarily in patients who are severely immunocompromised.


METHODS
We report a case of IPA that occurred in a 37-year-old woman with no history of previous immunosuppression or significant co-morbidity. She was admitted to our intensive care unit (ICU) with septic shock and multi-organ failure complicating a bacterial pneumonia. After an initial improvement, her condition deteriorated on the 10th day after admission with fever and lesions consistent with IPA seen on high-resolution computed tomography (HRCT). IPA was confirmed by isolating Aspergillus fumigatus from bronchoalveolar lavage and by a positive circulating galactomannan test (sandwich ELISA). First line therapy with voriconazole had to be stopped after 12 days due to hepatic toxicity. The patient was successfully treated with caspofungine for 2 months then itraconazole for 4 months with progressive improvement of HRCT abnormalities. Her galactomannan test became negative at 6 months.


CONCLUSIONS
The diagnosis of IPA must be considered in critically ill patients even in the absence of underlying immunosupression where suggestive HRCT abnormalities occur in the context of septic shock and multiple organ failure.
Nourry
L
L
Service de Pneumologie, CHU, Angers, France.
Gagnadoux
F
F
Pierrot
M
M
Gourdier
A L
AL
Mercat
A
A
Racineux
J L
JL
D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000175:diagnosis* / Q000188:drug therapy; D001232:Aspergillus fumigatus / Q000302:isolation & purification; D005260:Female; D006801:Humans; D008172:Lung Diseases, Fungal / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology*; D009102:Multiple Organ Failure / Q000150:complications / Q000188:drug therapy / Q000382:microbiology; D018410:Pneumonia, Bacterial / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology; D012772:Shock, Septic / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology
D000935:Antifungal Agents